Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation

Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation
Conditions:   Non Small Cell Lung Cancer;   Medullary Thyroid Cancer;   Colon Cancer;   Breast Cancer;   Pancreatic Cancer;   Papillary Thyroid Cancer;   Other Solid Tumors With Evidence of Activating RET Alteration
Intervention:   Drug: Selpercatinib
Sponsors:   Loxo Oncology, Inc.;   Eli Lilly and Company
Available

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

June 30, 2022Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments